A new target for malaria drug development
疟疾药物开发的新目标
基本信息
- 批准号:7327787
- 负责人:
- 金额:$ 31.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-02-01 至 2009-01-31
- 项目状态:已结题
- 来源:
- 关键词:Adenylate CyclaseAntigensAntimalarialsApplications GrantsBacteriaBicarbonatesBiochemicalBiologicalBiologyBuffersCandida albicansCarbon DioxideCell CycleCellsCessation of lifeChemicalsChildChloroflexiCollaborationsConditionCyanobacteriumDependenceDeveloped CountriesDeveloping CountriesDoseEffectivenessEmerging Communicable DiseasesEnzymesEquilibriumErythrocytesEukaryotaEukaryotic CellFalciparum MalariaGTP-Binding ProteinsGenesGenus MycobacteriumGrowthHealthcareHumanImmunologyInfectionLaboratoriesLeadLibrariesLifeLife Cycle StagesMalariaMammalsMedicalMicrobiologyOrganismPan GenusParasitesPersonal CommunicationPharmaceutical PreparationsPhysiologicalPlasmodiumPlasmodium falciparumRegulationRelative (related person)Research PersonnelResistanceResistance developmentResourcesSea UrchinsSignal PathwaySmall Molecule Chemical LibrarySurfaceSystemTestingTherapeuticVaccinesVector-transmitted infectious diseaseadenylyl cyclase 6collegecombinatorialcost effectivedrug developmentgene cloninggenome sequencinginhibitor/antagonistkillingssmall moleculesmall molecule libraries
项目摘要
DESCRIPTION (provided by applicant): Malaria is vector-borne disease infecting 200-300 million people per year worldwide. It is caused by infection of red blood cells by any one of four unicellular parasites from the genus Plasmodium. When caused by Plasmodium falciparum, malaria is life threatening, resulting in 1-2 million deaths, primarily in young children. Current treatments suffer from increasing resistance among parasites and efforts to develop a vaccine are severely limited by the Plasmodium life cycle; therefore, new treatments are needed. The recently sequenced genome of the most lethal malarial parasite, Plasmodium falciparum, revealed two adenylyl cyclase genes (PfACs) related to the bicarbonate responsive soluble adenylyl cyclases (sAC) in mammals and cyanobacteria. Their sequences predict the PfACs to be bicarbonate responsive, and we hypothesized that at least one is responsible for Plasmodium's absolute dependence on high levels of carbon dioxide/bicarbonate for viability. Therefore, the PfACs may represent new targets for an antimalarial drug. We treated P. falciparum with a small molecule (KH7) we developed which inhibits all sAC-like cyclases tested thus far, including sAC-like cyclases found in mammals, unicellular eukaryotes and bacteria. Parasites cultured in red blood cells were killed by KH7 in a dose dependent manner within a single cell cycle. A structurally related compound (KH7.15) which is inert towards sAC-like cyclases had no effect on parasite growth. In this grant application, we propose to clone and characterized the two PfAC cyclases and confirm whether they are the target of KH7 lethality. If the PfACs are validated as targets for new antimalarial drugs, we propose to use purified Plasmodium cyclases to screen a chemical library to identify compounds selective for Plasmodium cyclases relative to human sAC.
描述(由申请人提供):疟疾是一种媒介传播的疾病,全世界每年有2 -3亿人感染。该病由四种疟原虫属单细胞寄生虫中的任何一种感染红细胞引起。当由恶性疟原虫引起时,疟疾会危及生命,导致1至200万人死亡,主要是幼儿。目前的治疗方法受到寄生虫耐药性日益增强的影响,而且开发疫苗的努力受到疟原虫生命周期的严重限制;因此,需要新的治疗方法。最近对最致命的疟原虫恶性疟原虫的基因组测序发现,哺乳动物和蓝藻中的两个腺苷酸环化酶基因(PfACs)与碳酸氢盐反应性可溶性腺苷酸环化酶(sAC)相关。它们的序列预测了pfac对碳酸氢盐的反应,我们假设至少有一个是疟原虫对高水平二氧化碳/碳酸氢盐生存的绝对依赖的原因。因此,pfac可能是抗疟药物的新靶点。我们用我们开发的一种小分子(KH7)治疗恶性疟原虫,这种小分子可以抑制迄今为止测试过的所有sac样环化酶,包括在哺乳动物、单细胞真核生物和细菌中发现的sac样环化酶。在红细胞中培养的寄生虫被KH7在单个细胞周期内以剂量依赖的方式杀死。一种结构相关的化合物(KH7.15)对sac样环化酶具有惰性,对寄生虫的生长没有影响。在本次拨款申请中,我们拟克隆并表征这两种PfAC环化酶,并确认它们是否是KH7致死的目标。如果pfac被证实为新的抗疟疾药物的靶点,我们建议使用纯化的疟原虫环化酶筛选化学文库,以确定相对于人类sAC的疟原虫环化酶选择性化合物。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Crystal structure and regulation mechanisms of the CyaB adenylyl cyclase from the human pathogen Pseudomonas aeruginosa.
人类病原体铜绿假单胞菌 CyaB 腺苷酸环化酶的晶体结构和调节机制。
- DOI:10.1016/j.jmb.2011.12.045
- 发表时间:2012
- 期刊:
- 影响因子:5.6
- 作者:Topal,Hüsnü;Fulcher,NanetteB;Bitterman,Jacob;Salazar,Eric;Buck,Jochen;Levin,LonnyR;Cann,MartinJ;Wolfgang,MatthewC;Steegborn,Clemens
- 通讯作者:Steegborn,Clemens
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LONNY R LEVIN其他文献
LONNY R LEVIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LONNY R LEVIN', 18)}}的其他基金
Optimization of in vivo validated ADCY10 inhibitors
体内验证的 ADCY10 抑制剂的优化
- 批准号:
10747156 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Neuronal growth factor signaling via cAMP
通过 cAMP 的神经元生长因子信号传导
- 批准号:
7342124 - 财政年份:2007
- 资助金额:
$ 31.25万 - 项目类别:
Neuronal growth factor signaling via cAMP
通过 cAMP 的神经元生长因子信号传导
- 批准号:
7194673 - 财政年份:2007
- 资助金额:
$ 31.25万 - 项目类别:
Neuronal growth factor signaling via cAMP
通过 cAMP 的神经元生长因子信号传导
- 批准号:
7738937 - 财政年份:2007
- 资助金额:
$ 31.25万 - 项目类别:
Neuronal growth factor signaling via cAMP
通过 cAMP 的神经元生长因子信号传导
- 批准号:
7535181 - 财政年份:2007
- 资助金额:
$ 31.25万 - 项目类别:
Neuronal growth factor signaling via cAMP
通过 cAMP 的神经元生长因子信号传导
- 批准号:
7935631 - 财政年份:2007
- 资助金额:
$ 31.25万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 31.25万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 31.25万 - 项目类别: